Real-world experience with CPX-351 in high-risk acute myeloid leukemia

被引：6

作者：

Lemoli, Roberto M. ^{[1
,2
,5
,6
]}

Montesinos, Pau ^{[3
]}

Jain, Akriti ^{[4
]}

机构：

[1] IRCCS Osped Policlin San Martino, Genoa, Italy

[2] Univ Genoa, Clin Hematol, Genoa, Italy

[3] Hosp Univ & Politecn La Fe, Valencia, Spain

[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[5] IRCCS Osped Policlin San Martino, Clin Hematol, Viale Benedetto XV,6, I-16132 Genoa, GE, Italy

[6] Univ Genoa, Dept Internal Med & Med Specialties, Viale Benedetto XV,6, I-16132 Genoa, GE, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2023年 / 185卷

关键词：

AML; Chemotherapy; CPX-351; Cytarabine; Daunorubicin; Real; -world; Measurable residual disease; RESIDUAL DISEASE; AML PATIENTS; SECONDARY; CHEMOTHERAPY; DAUNORUBICIN; AZACITIDINE; VENETOCLAX; CYTARABINE; ADULTS; AGE;

D O I：

10.1016/j.critrevonc.2023.103984

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CPX-351, a dual-drug liposomal encapsulation of daunorubicin/cytarabine, was approved for newly diagnosed therapy-related acute myeloid leukemia (AML) and AML with myelodysplasia-related changes in adults in 2017 (US; updated to patients aged & GE;1 year in 2021) and 2018 (EU/UK) based on improved survival and remission and comparable safety versus 7 + 3 chemotherapy in a randomized trial in older adults. Real-world studies have since evaluated CPX-351 in routine practice across several countries and addressed important data gaps (e.g., use in younger adults, measurable residual disease negativity, outcomes by mutation). This review discusses realworld studies of CPX-351 as AML treatment, with the aim of helping prescribers make informed treatment decisions.

引用

页数：10

共 50 条

[21] Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia
Villa, Kathleen F.
Ryan, Robert J.
Chiarella, Michael
Louie, Arthur C.
JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (07) : 714 - 720
[22] CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia
Talati, Chetasi
Lancet, Jeffrey E.
FUTURE ONCOLOGY, 2018, 14 (12) : 1147 - 1154
[23] Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Alotaibi, Shaykhah
Niederwieser, Dietger
Ahmed, Syed Osman
Sanz, Jaime
Mohty, Mohamad
Aljurf, Mahmoud
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (08): : 575 - 580
[24] Optimal Timing for Response Assessment in Acute Myeloid Leukemia Patients Treated with CPX-351 Induction: Real World Experience from 8 Spanish Hospitals
Villalobos, Manuel Jorge Fernandez
Ortiz, Javier
Alvarez, Angela Figuera
De Miguel, Carlos
De Laiglesia, Almudena
Fernandez, Virginia Pradillo
Beya, Marina Diaz
Esteve, Jordi
Polo, Marta
Olave, Mayte
Moles, Maria del Mar
Pimentel, Amparo
Garcia-Sanz, Ramon
Macias, Gabriela Rodriguez
BLOOD, 2024, 144 : 4285 - 4286
[25] Phase 2 Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia
Jen, Wei-Ying
DiNardo, Courtney D.
Chien, Kelly S.
Alvarado-Valero, Yesid
Masarova, Lucia
Brandt, Mark
Bull-Linderman, Debra
Daver, Naval
Montalban-Bravo, Guillermo
Bataller, Alex
Garcia-Manero, Guillermo
Issa, Ghayas C.
Alousi, Amin
Short, Nicholas J.
Ravandi, Farhad
Kadia, Tapan M.
BLOOD, 2023, 142
[26] A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX
Rodriguez-Arboli, Eduardo
Rodriguez-Veiga, Rebeca
Soria-Saldise, Elena
Bergua, Juan M.
Caballero-Velazquez, Teresa
Arnan, Montserrat
Vives, Susana
Serrano, Josefina
Bernal, Teresa
Martinez-Sanchez, Pilar
Tormo, Mar
Rodriguez-Medina, Carlos
Herrera-Puente, Pilar
Lavilla-Rubira, Esperanza
Boluda, Blanca
Acuna-Cruz, Evelyn
Cano, Isabel
Caceres, Sara
Ballesteros, Juan
Falantes, Jose
Martinez-Cuadron, David
Perez-Simon, Jose A.
Montesinos, Pau
CANCER, 2025, 131 (01)
[27] Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry
Bernal, Teresa
Fernandez Moreno, Ainhoa
de LaIglesia, Almudena
Benavente, Celina
Garcia-Noblejas, Ana
Garcia Belmonte, Daniel
Riaza, Rosalia
Salamero, Olga
Angeles Foncillas, Maria
Roldan, Alicia
Noriega Concepcion, Victor
Llorente Gonzalez, Laura
Bergua Burgues, Juan Miguel
Lorente de Una, Soraya
Rodriguez-Macias, Gabriela
de la Fuente Burguera, Adolfo
Garcia Perez, Maria Jose
Lopez-Lorenzo, Jose Luis
Martinez, Pilar
Alaez, Concepcion
Callejas, Marta
Martinez-Chamorro, Carmen
Rifon Roca, Jose
Amador Barciela, Lourdes
Mena Duran, Armando V.
Gomez Correcha, Karoll
Lavilla Rubira, Esperanza
Luz Amigo, Maria
Vall-llovera, Ferran
Garrido, Ana
Garcia-Fortes, Maria
de Miguel Llorente, Dunia
Aules Leonardo, Anastasia
Cervero, Carlos
Coll Jorda, Rosa
Perez-Encinas, Manuel M.
Polo Zarzuela, Marta
Figuera, Angela
Rad, Guillermo
Martinez-Cuadron, David
Montesinos, Pau
CANCER MEDICINE, 2023, 12 (14): : 14892 - 14901
[28] Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia
Roboz, Gail J.
Larson, Melissa L.
Rubenstein, S. Eric
Solomon, Scott R.
Schiller, Gary J.
An, Qi
Chiarella, Michael
Louie, Arthur C.
Lin, Tara L.
LEUKEMIA & LYMPHOMA, 2020, 61 (05) : 1188 - 1194
[29] CPX-351 Population Pharmacokinetics in Pediatric and Adult Patients with Acute Myeloid Leukemia (AML)
Wang, Qi
Cooper, Todd M.
Absalon, Michael J.
Kolb, E. Anders
Vasilinin, Grygoriy
Gosselin, Nathalie H.
Alonzo, Todd A.
Marier, J. F.
BLOOD, 2020, 136
[30] CPX-351 ASSOCIATED RASH IN PEDIATRIC PATIENTS WITH ACUTE MYELOID LEUKEMIA: A CASE SERIES
Weisnicht, Allison
Chan, Audrey
Stevens, Alexandra
PEDIATRIC BLOOD & CANCER, 2023, 70 : S56 - S56

← 1 2 3 4 5 →